background
detect
hepat
e
viru
hev
rna
faec
use
diagnos
monitor
hev
infect
particularli
immunocompromis
patient
requir
ribavirin
therapi
object
studi
evalu
perform
altona
realstar
hev
rna
kit
detect
quantifi
hev
faec
studi
design
rna
extract
stool
sampl
two
method
qiaamp
viral
rna
mini
kit
magna
pure
autom
altona
result
compar
refer
laboratorydevelop
accredit
rtpcr
assay
result
altona
refer
assay
detect
hev
rna
qiaamp
extract
sampl
respect
exclus
invalid
result
detect
hev
rna
magna
pure
extract
sampl
respect
emphas
import
rna
extract
method
hev
rna
concentr
obtain
altona
rtpcr
refer
rtpcr
well
correl
whatev
extract
method
bland
altman
analys
indic
altona
valu
higher
refer
assay
valu
altona
valu
qiaampextract
magna
pureextract
hev
rna
similar
conclus
altona
realstar
assay
suitabl
quantifi
hev
rna
faec
monitor
hev
rna
shed
ribavirin
therapi
extract
critic
detect
faecal
hev
high
perform
rtpcr
assay
last
year
becom
appar
hepat
e
viru
hev
pathogen
global
signific
hev
infect
among
frequent
caus
acut
hepat
worldwid
hev
strain
infect
human
classifi
one
major
genotyp
peak
viremia
occur
incub
period
earli
phase
diseas
patient
acut
hev
infect
viral
rna
detect
blood
faec
patient
onset
clinic
symptom
persist
blood
becom
undetect
week
later
onset
symptom
remain
faec
longer
chronic
hev
infect
report
solidorgan
transplant
recipi
hematolog
patient
given
chemotherapi
patient
infect
human
immunodefici
viru
hiv
low
count
chronic
hev
infect
defin
persist
hev
replic
three
month
chronic
infect
caus
genotyp
genotyp
may
rapidli
evolv
cirrhosi
loss
liver
graft
ribavirin
becom
drug
choic
treat
chronic
hev
infect
immunocompromis
decreas
hev
rna
blood
log
copiesml
greater
day
initi
ribavirin
therapi
predict
respons
detect
hev
rna
faec
despit
neg
hev
rna
blood
strong
predictor
relaps
immunocompromis
subject
therefor
monitor
hev
faecal
excret
could
help
determin
optim
durat
http
ribavirin
therapi
recommend
manag
chronic
hev
infect
solidorgan
transplant
recipi
howev
presenc
pcr
inhibitor
particular
matrix
make
detect
hev
rna
difficult
commerci
hev
rna
assay
present
valid
faecal
sampl
evalu
perform
two
rna
extract
method
commerci
assay
altona
hev
rtpcr
kit
compar
laboratorydevelop
test
ldt
detect
quantifi
hev
rna
faec
determin
quantit
analyt
perform
altona
assay
two
clinic
set
hev
shed
acut
hepat
e
monitor
ribavirin
therapi
test
laboratori
faecal
sampl
patient
hev
infect
assess
detect
hev
rna
blood
iso
assay
ldt
patient
follow
toulous
univers
hospit
ten
sampl
collect
acut
phase
infect
one
month
increas
alt
untreat
patient
solidorgantranspl
recipi
chronic
hev
genotyp
transplant
recipi
treat
ribavirin
monotherapi
month
sever
faecal
sampl
collect
n
n
treatment
sustain
virolog
respons
defin
neg
blood
hev
rna
month
treatment
relaps
defin
posit
blood
hev
rna
treatment
withdraw
faecal
sampl
mg
weight
suspend
ml
minimum
essenti
eagl
medium
mem
sigmaaldricht
franc
vortex
frozen
h
centrifug
rpm
min
result
supernat
pass
filter
filtrat
use
hev
rna
extract
quantif
real
time
rtpcr
nonintervent
studi
includ
addit
procedur
biolog
materi
clinic
data
obtain
standard
viral
diagnosi
follow
physician
order
specif
sampl
modifi
sampl
protocol
question
addit
nation
standard
questionnair
data
analys
use
anonym
databas
french
public
health
law
csp
art
l
requir
written
inform
consent
protocol
hev
rna
eluat
quantifi
use
iso
ldt
refer
rtpcr
assay
ldt
intern
control
also
quantifi
use
altona
hev
rtpcr
version
kit
commerci
assay
intern
control
altona
rtpcr
kit
ad
rtpcr
mix
prepar
hev
rna
quantifi
assay
calcul
standard
curv
gener
serial
dilut
transcrib
rna
standard
limit
quantif
assay
copiesg
hev
rna
valu
log
transform
analys
graphpad
prism
softwar
spearman
test
use
test
correl
two
assay
p
valu
less
taken
indic
statist
signific
blandaltman
analysi
scatter
plot
differ
pair
measur
plot
mean
use
sampl
posit
method
assess
magnitud
disagr
estim
overal
bia
sampl
test
altona
assay
refer
rtpcr
altona
intern
control
neg
one
sampl
indic
inhibit
rtpcr
sampl
test
posit
refer
assay
hev
rna
log
copiesg
sampl
exclud
analysi
altona
rtpcr
detect
hev
rna
sampl
refer
rtpcr
detect
hev
rna
p
tabl
sampl
test
neg
altona
assay
test
posit
refer
assay
hev
rna
log
copiesg
thu
assay
concord
faecal
sampl
sampl
test
posit
neg
assay
tabl
altona
rtpcr
refer
rtpcr
hev
rna
concentr
correl
p
fig
altona
assay
valu
higher
refer
assay
valu
blandaltman
analysi
fig
produc
mean
deviat
assay
result
log
cg
differ
log
copiesg
sampl
tabl
sampl
posit
altona
assay
hev
rna
log
copiesg
neg
refer
assay
altona
assay
neg
sampl
posit
refer
assay
hev
rna
copiesg
hev
rna
concentr
obtain
altona
rtpcr
refer
rtpcr
correl
p
fig
altona
assay
valu
higher
refer
assay
blandaltman
analysi
fig
gave
mean
deviat
refer
rtpcr
altona
result
log
cg
bia
log
copiesg
sampl
hev
rna
detect
frequent
qiaamp
extract
magna
pure
extract
differ
signific
p
hev
rna
concentr
obtain
altona
rtpcr
qiaamp
extract
magna
pure
extract
correl
p
fig
altonaqiaamp
valu
altonamagna
pure
valu
also
similar
mean
deviat
log
cg
fig
bia
log
copiesg
sampl
altona
rtpcr
assay
found
median
hev
rna
concentr
faec
sampl
untreat
patient
log
copiesg
faec
plasma
hev
rna
concentr
patient
treat
ribavirin
decreas
viremia
becam
undetect
patient
one
month
ribavirin
therapi
patient
month
ribavirin
therapi
viremia
remain
undetect
end
treatment
altona
assay
found
faecal
shed
hev
rna
decreas
cours
ribavirin
fig
patient
test
posit
hev
rna
end
treatment
relaps
evalu
altona
real
star
rtpcr
kit
detect
quantifi
hev
rna
faec
two
rna
extract
method
indic
altona
assay
perform
well
find
correl
refer
rtpcr
test
previous
investig
perform
altona
rtpcr
assay
detect
hev
rna
plasma
analyt
sensit
good
highli
reproduc
present
studi
evalu
assay
detect
hev
rna
faec
valu
obtain
altona
refer
assay
highli
correl
refer
assay
gave
lower
hev
rna
valu
regardless
extract
method
altona
kit
may
amplifi
target
region
genom
effici
refer
assay
rtpcr
assay
found
posit
sampl
qiaamp
extract
magna
pure
treatment
although
differ
signific
clearli
rna
extract
method
import
mani
pcr
inhibitor
presum
affect
directli
rna
enzym
reaction
sever
inhibitor
found
faec
polysaccharid
chlorophyl
origin
veget
bile
salt
urea
glycolipid
heparin
qiaamp
kit
valid
extract
virus
food
studi
indic
suitabl
extract
hev
rna
faec
effici
rna
extract
method
remov
inhibitor
debri
produc
nucleic
acid
extract
high
puriti
significantli
affect
detect
target
rtpcr
studi
evalu
six
commerci
extract
platform
detect
sar
coronaviru
frm
faec
indic
magna
pure
method
perform
less
well
autom
platform
use
magnet
bead
minimag
magazorb
cortex
biochem
inhibitor
also
remov
faecal
sampl
sampl
dilut
use
less
faec
success
altona
retest
neg
sampl
altona
assay
intern
control
introduc
rtpcr
mix
thu
act
amplif
control
control
perform
pcr
limit
refer
ldt
assay
absenc
intern
control
nevertheless
neg
intern
control
alway
seen
result
hev
rnaposit
refer
rtpcr
hev
rnaneg
altona
rtpcr
moreov
altona
assay
packag
insert
indic
intern
control
also
place
lysi
buffer
extract
may
evalu
inhibit
better
challeng
matric
faec
also
measur
viru
shed
faec
treat
untreat
patient
median
hev
rna
concentr
untreat
patient
log
copiesg
faec
hev
rna
concentr
faec
similar
shed
enter
virus
sabria
et
al
report
viru
concentr
log
copiesg
symptomat
asymptomat
patient
noroviru
infect
high
faecal
hev
rna
load
keep
recent
observ
hevinfect
humanliv
chimer
mice
hev
rna
concentr
higher
correspond
plasma
sampl
find
ribavirin
therapi
gradual
reduc
hev
rna
concentr
faec
hev
shed
faec
longer
hev
viremia
persist
patient
data
indic
altona
rtpcr
assay
use
follow
dynam
hev
shed
faec
extend
treatment
patient
still
hev
faec
end
ribavirin
therapi
monitor
hev
faecal
excret
recommend
determin
optim
durat
ribavirin
therapi
qualit
assay
could
suffici
valid
quantit
assay
assess
declin
residu
faecal
viru
shed
ribavirin
therapi
conclud
altona
rtpcr
assay
suitabl
quantifi
hev
rna
faec
particularli
monitor
hev
rna
shed
ribavirin
therapi
extract
may
influenc
hev
rna
detect
faec
sampl
laboratori
valid
extract
protocol
matric
author
contribut
florenc
abravanel
lhomm
jacqu
izopet
design
studi
wrote
manuscript
jeanmari
peron
laurent
alric
nassim
kamar
design
studi
follow
patient
review
manuscript
audrey
martin
duboi
luce
minier
perform
virolog
analys
hev
rtpcr
kit
kindli
provid
altona
nation
refer
center
hepat
e
support
grant
french
public
health
author
